Liječnički vjesnik, Vol. 133 No. 1-2, 2011.
Other
TEN YEARS AFTER PUBLISHING RESULTSFROM THE HEART OUTCOMES PREVENTION EVALUATION STUDY – HOPE:IMPLICATIONS ON TREATMENT WITH ANGIOTENSIN CONVERTING ENZYME INHIBITORSIN CLINICAL PRACTICE
Darko Počanić
Abstract
Ten years ago results from The Heart Outcomes Prevention Evaluation Study were published. Those results had
a great impact on position of ACE inhibitors in clinical practice. In the study, comparsion of ramipril in daily dosage up to
10 mg and placebo in 9541 patients with high cardiovascular risk during 4.5 years of follow-up resulted in relative risk
reduction for all primary end-points: cardiovascular mortality, myocardial infarction and stroke for 22% in patients treated
with ramipril. Systolic blood pressure was reduced minimally for 3 mmHg. The effect was indipendent of age, gender,
concomitant diseases or therapy. Extended follow-up of the patients for further 2.6 years showed prolonged beneficial effect
of ramipril. Ramipril reduced relative risk for newly developed diabetes for 34%. Results of the study greatly influenced
the guidelines for treatment of patients with cardiovascular diseases. This study proved benefits of ACE inhibitors in primary
prevention in patients with high cardiovascular risk
Keywords
Angiotensin-converting enzyme inhibitors – therapeutic use; Ramipril – therapeutic use; Cardiovascular diseases – drug therapy, mortality, prevention and control; Myocardial infarction – mortality, prevention and control; Stroke – mortality, prevention and control; Diabetes complications – prevention and control
Hrčak ID:
171657
URI
Publication date:
28.2.2011.
Visits: 1.335 *